Bergenbio ASA
OSE:BGBIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.683
33.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bergenbio ASA
Other Operating Expenses
Bergenbio ASA
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
Other Operating Expenses
-kr107.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Other Operating Expenses
-kr87.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-9%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Other Operating Expenses
-kr12.3m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Other Operating Expenses
-kr34.7m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-9%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Other Operating Expenses
-$32.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Other Operating Expenses
-kr11.7m
|
CAGR 3-Years
66%
|
CAGR 5-Years
47%
|
CAGR 10-Years
9%
|
|
Bergenbio ASA
Glance View
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
See Also
What is Bergenbio ASA's Other Operating Expenses?
Other Operating Expenses
-107.3m
NOK
Based on the financial report for Sep 30, 2024, Bergenbio ASA's Other Operating Expenses amounts to -107.3m NOK.
What is Bergenbio ASA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
8%
Over the last year, the Other Operating Expenses growth was 25%. The average annual Other Operating Expenses growth rates for Bergenbio ASA have been 21% over the past three years , 8% over the past five years .
You don't have any saved screeners yet
